Page last updated: 2024-08-24

valsartan and Body Weight

valsartan has been researched along with Body Weight in 47 studies

Research

Studies (47)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (10.64)	18.2507
2000's	22 (46.81)	29.6817
2010's	17 (36.17)	24.3611
2020's	3 (6.38)	2.80

Authors

Authors	Studies
Grime, K; Paine, SW	1
Barrow, BM; Castillo, JJ; Cronic, L; Esser, N; Hackney, DJ; Hogan, MF; Hull, RL; Mongovin, SM; Schmidt, C; Templin, AT; Zraika, S	1
Asghari, AA; Hosseini, SJ; Mahmoudabady, M; Mousavi Emadi, Z; Salmani, H	1
Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X	1
Inoue, R; Kouhei, Y; Mochizuki, H; Murota, N; Nii, K; Nishime, C; Sato, SI; Taniguchi, M; Tsutsumi, H	1
Campbell, DJ; Koid, SS; Ziogas, J	1
Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y	1
Atanasovska, E; Cekovska, S; Gjorgjievska, K; Jurhar-Pavlova, M; Pavlovska, K; Zafirov, D; Zendelovska, D	1
Bai, F; Chang, P; Li, X; Lin, X; Wang, Q; Xu, H; Yang, M; Yu, J; Zhang, X; Zhang, Z; Zhao, F; Zhao, X	1
Califf, RM; Davies, MJ; Gill, JM; Haffner, SM; Holman, RR; Kraus, WE; McMurray, JJ; Preiss, D; Thomas, LE; Wojdyla, DM; Yates, T	1
Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O	1
Abadir, PM; Abdel-Rahman, EM; Siragy, HM	1
Batisky, DL; Blumer, J; Shi, V; Solar-Yohay, S; Sunkara, G; Wells, T	1
Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R	1
Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J	2
Gao, Q; Liu, Z; Qin, W; Shen, W; Wang, J; Wang, S; Zeng, C; Zhang, M; Zheng, C; Zhu, X	1
Imig, JD; Khan, AH	1
Abraham, I; Brié, H; Cholette, M; Ciesielski, G; Hermans, C; Kinsey, K; Lee, C; MacDonald, K; Pacheco, C; Reel, S; Song, M; Speaks, P; Van der Niepen, P; Vancayzeele, S; Yee, B	1
Chen, C; Le, X; Sun, S; Tang, Y; Wang, M; Yin, Y	1
Horiguchi, CS; Makino, H; Miyoshi, T; Murakami, K; Nakamura, Y; Ogawa, D; Sasaki, M; Uchida, HA; Wada, J	1
Aritomi, S; Jin, D; Miyazaki, M; Niinuma, K; Takai, S	1
Ando, H; Fujimura, A; Ishikawa-Kobayashi, E; Maekawa, T; Nozawa, M; Shiga, T; Takuma, M; Ushijima, K	1
Benigni, A; Donadoni, C; Fassi, A; Gagliardini, E; Lepre, MS; Remuzzi, A; Remuzzi, G; Sangalli, F	1
Awad, AS; Carey, RM; Siragy, HM; Webb, RL	2
Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y	1
Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E	1
Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H	1
Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW	1
Hirose, H; Komiya, N; Saisho, Y	1
Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M	1
Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL	1
Huang, J; Siragy, HM	1
Chow, L; De Gasparo, M; Levens, N	1
Scheidegger, KJ; Struijker-Boudier, HA; van Essen, H; Wood, JM	1
Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S	1
Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S	1
De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C	1
Finckenberg, P; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H	1
Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H	1
Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E	1
Hayashida, W; Yasaka, A	1
Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R	1
Benetos, A; de Gasparo, M; Labat, C; Lacolley, P; Lajemi, M; Safar, ME	1
Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I	1
Bonnet, F; Burns, WC; Candido, R; Cao, Z; Carey, RM; Cooper, ME; De Gasparo, M; Kawachi, H; Nesteroff, SP; Shimizu, F	1

Trials

6 trial(s) available for valsartan and Body Weight

Article	Year
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ open, 2015, Aug-14, Volume: 5, Issue:8 Topics: Body Weight; Cyclohexanes; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Valsartan	2015
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. Journal of human hypertension, 2008, Volume: 22, Issue:8 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertension; Incidence; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan	2008
Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. Journal of clinical pharmacology, 2009, Volume: 49, Issue:2 Topics: Administration, Oral; Adolescent; Age Factors; Antihypertensive Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Infant; Male; Tetrazoles; Valine; Valsartan	2009
Effect of nateglinide on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan	2010
Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England journal of medicine, 2010, Apr-22, Volume: 362, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan	2010
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diabetes & vascular disease research, 2013, Volume: 10, Issue:1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypertension; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Subcutaneous Fat; Telmisartan; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome; Valine; Valsartan; Waist Circumference	2013

Other Studies

41 other study(ies) available for valsartan and Body Weight

Article	Year
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Body Weight; Dogs; Drug Administration Routes; Humans; Liver; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Pharmaceutical Preparations; Protein Binding; Rats; Species Specificity	2013
Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in endocrinology, 2022, Volume: 13 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Insulin Resistance; Insulins; Mice; Mice, Inbred C57BL; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan	2022
Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes. Journal of food biochemistry, 2022, Volume: 46, Issue:12 Topics: Animals; Body Weight; Cardiomegaly; Diabetes Mellitus, Experimental; Fibrosis; Rats; Valsartan	2022
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism. Life sciences, 2021, Feb-01, Volume: 266 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan	2021
Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets. The Journal of toxicological sciences, 2018, Volume: 43, Issue:11 Topics: Administration, Oral; Animal Welfare; Animals; Body Weight; Callithrix; Eating; Erythrocytes; Female; Male; Toxicity Tests; Toxicokinetics; Valsartan; Vomiting	2018
Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:4 Topics: Amides; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Female; Fumarates; Imidazoles; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan	2014
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice. Molecular medicine (Cambridge, Mass.), 2015, Feb-09, Volume: 21 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Disease Models, Animal; Inflammation; Interleukin-5; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; T-Lymphocyte Subsets; Th2 Cells; Valsartan	2015
Protective effects of AT1-receptor blocker and CA antagonist combination on renal function in salt loaded spontaneously hypertensive rats. Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 2015, Volume: 36, Issue:1 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Creatinine; Hydrogen-Ion Concentration; Kidney; Kidney Function Tests; Male; Proteinuria; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Urine; Valsartan	2015
Tetrahydrobiopterin reverse left ventricular hypertrophy and diastolic dysfunction through the PI3K/p-Akt pathway in spontaneously hypertensive rats. Biochemical and biophysical research communications, 2015, Aug-07, Volume: 463, Issue:4 Topics: Animals; Biopterins; Blood Pressure; Body Weight; Diastole; Hypertension; Hypertrophy, Left Ventricular; Male; Organ Size; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan	2015
Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors. American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 295, Issue:5 Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Kidney; Male; Microdialysis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan	2008
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:3 Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan	2010
Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Chemokine CCL2; Desmin; Diabetic Nephropathies; Diterpenes; Epoxy Compounds; Glomerular Filtration Rate; Immunohistochemistry; Kidney; Lipids; Liver; Mice; Mice, Inbred C57BL; Microscopy, Electron; Phenanthrenes; Podocytes; Reactive Oxygen Species; T-Lymphocytes; Tetrazoles; Valine; Valsartan	2010
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. American journal of hypertension, 2011, Volume: 24, Issue:7 Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Dietary Fats; Disease Models, Animal; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2011
Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study). Nutrition, metabolism, and cardiovascular diseases : NMCD, 2013, Volume: 23, Issue:4 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Belgium; Blood Pressure; Body Mass Index; Body Weight; Clinical Competence; Female; Guideline Adherence; Humans; Hypertension; Linear Models; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Overweight; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan	2013
Cardiovascular protection with danshensu in spontaneously hypertensive rats. Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:10 Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Cardiotonic Agents; Cardiovascular System; Chronic Disease; Drug Administration Schedule; Drug Evaluation, Preclinical; Heart; Heart Function Tests; Hypertension; Lactates; Large-Conductance Calcium-Activated Potassium Channels; Male; Mesenteric Arteries; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Patch-Clamp Techniques; Phytotherapy; Plant Preparations; Plant Roots; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan	2011
Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:4 Topics: Aldehydes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Carotid Arteries; Cysteine Proteinase Inhibitors; Dihydropyridines; Heart; Immunohistochemistry; Male; Muscle Relaxation; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type III; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan; Vascular Diseases	2013
Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. European journal of pharmacology, 2013, Jan-05, Volume: 698, Issue:1-3 Topics: Adiponectin; Adipose Tissue; Animals; Benzimidazoles; Benzoates; Body Weight; Diabetes Mellitus; Eating; Fatty Acid Synthases; Fatty Acid-Binding Proteins; Gene Expression Regulation; Homeostasis; Insulin Resistance; Interleukin-6; Male; Mice; Mice, Obese; PPAR gamma; RNA, Messenger; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan	2013
Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney international, 2002, Volume: 62, Issue:3 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Collagen Type III; Disease Progression; Kidney Diseases; Kidney Glomerulus; Lisinopril; Macrophages; Male; Monocytes; Proteinuria; Rats; Rats, Wistar; Renal Circulation; Tetrazoles; Valine; Valsartan	2002
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. Journal of hypertension, 2004, Volume: 22, Issue:8 Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Fluid; Kidney; Losartan; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan	2004
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. Life sciences, 2004, Aug-27, Volume: 75, Issue:15 Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan	2004
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan	2004
Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats. American journal of hypertension, 2005, Volume: 18, Issue:4 Pt 1 Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Extracellular Fluid; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Thromboxane B2; Valine; Valsartan	2005
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochemical and biophysical research communications, 2005, Jul-15, Volume: 332, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan	2005
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. Journal of biomedical science, 2005, Volume: 12, Issue:2 Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; Carbazoles; Carvedilol; Down-Regulation; Doxazosin; Echocardiography; Hemodynamics; Hypertrophy; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Myocardium; Nerve Growth Factor; Organ Size; Pressure; Propanolamines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transcription Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vasodilator Agents	2005
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes research and clinical practice, 2006, Volume: 74, Issue:2 Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycosylation; Humans; Hypertension; Japan; Tetrazoles; Thiobarbituric Acid Reactive Substances; Valine; Valsartan	2006
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life sciences, 2006, Dec-03, Volume: 80, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Male; Mice; Mice, Knockout; Myocardial Infarction; Organ Size; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling	2006
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. American journal of hypertension, 2007, Volume: 20, Issue:4 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atenolol; Blood Pressure; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Female; Glycated Hemoglobin; Rats; Rats, Sprague-Dawley; Renin; Retinal Vessels; Tetrazoles; Valine; Valsartan	2007
Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Experimental physiology, 2008, Volume: 93, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Imidazoles; Immunohistochemistry; Kidney Glomerulus; Kidney Tubules; NADPH Oxidases; Onium Compounds; Prorenin Receptor; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Up-Regulation; Valine; Valsartan	2008
Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. European journal of pharmacology, 1995, Aug-25, Volume: 282, Issue:1-3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Glucose; Blood Pressure; Body Weight; Drug Tolerance; Glucose Intolerance; Hypertension; Insulin Resistance; Lipids; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan	1995
Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 278, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Body Weight; Hemodynamics; Hypertension; Male; Microcirculation; Muscle, Skeletal; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan	1996
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment. Arzneimittel-Forschung, 1997, Volume: 47, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan	1997
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan. Arzneimittel-Forschung, 1997, Volume: 47, Issue:5 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left	1997
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundamental & clinical pharmacology, 1999, Volume: 13, Issue:6 Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents	1999
Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats. European journal of pharmacology, 2000, Jun-09, Volume: 398, Issue:1 Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cyclosporine; Dose-Response Relationship, Drug; Enalapril; Hypertension; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Rats; Rats, Inbred SHR; Renal Artery; Systole; Tetrazoles; Valine; Valsartan; Vasoconstriction; Vasodilation	2000
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. British journal of pharmacology, 2000, Volume: 130, Issue:6 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin Receptor Antagonists; Cyclosporine; Dose-Response Relationship, Drug; Drinking; Eating; Electrolytes; Enalapril; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Kallikreins; Kidney; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin; Sodium, Dietary; Tetrazoles; Urination; Valine; Valsartan	2000
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2 Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan	2001
Alterations of load-induced p38 MAP kinase activation in failing rat hearts. Biochemical and biophysical research communications, 2001, Jul-13, Volume: 285, Issue:2 Topics: Animals; Antihypertensive Agents; Body Weight; Diastole; Enzyme Activation; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Organ Size; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred Dahl; Reference Values; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Weight-Bearing	2001
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation, 2001, Sep-18, Volume: 104, Issue:12 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan	2001
Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 38, Issue:3 Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Carotid Arteries; Dose-Response Relationship, Drug; Fibronectins; Hypertension; Immunohistochemistry; Male; Protein Isoforms; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan	2001
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta histochemica, 2002, Volume: 104, Issue:2 Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan	2002
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:7 Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Body Weight; Cytoprotection; Diuresis; Gene Expression; Imidazoles; Kidney; Kidney Diseases; Male; Membrane Proteins; Nephrectomy; Organ Size; Proteins; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan	2002